KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nektar Therapeutics (NKTR) Gross Margin (2016 - 2025)

Historic Gross Margin for Nektar Therapeutics (NKTR) over the last 16 years, with Q3 2025 value amounting to 12.66%.

  • Nektar Therapeutics' Gross Margin fell 416900.0% to 12.66% in Q3 2025 from the same period last year, while for Sep 2025 it was 25.74%, marking a year-over-year decrease of 270100.0%. This contributed to the annual value of 57.28% for FY2024, which is 16100.0% down from last year.
  • Latest data reveals that Nektar Therapeutics reported Gross Margin of 12.66% as of Q3 2025, which was down 416900.0% from 7.62% recorded in Q2 2025.
  • In the past 5 years, Nektar Therapeutics' Gross Margin registered a high of 78.95% during Q3 2022, and its lowest value of 65.01% during Q1 2025.
  • Moreover, its 5-year median value for Gross Margin was 67.31% (2023), whereas its average is 54.01%.
  • Its Gross Margin has fluctuated over the past 5 years, first skyrocketed by 147300bps in 2024, then plummeted by -1132300bps in 2025.
  • Quarter analysis of 5 years shows Nektar Therapeutics' Gross Margin stood at 75.36% in 2021, then decreased by -5bps to 71.7% in 2022, then fell by -22bps to 55.78% in 2023, then rose by 26bps to 70.51% in 2024, then crashed by -82bps to 12.66% in 2025.
  • Its Gross Margin was 12.66% in Q3 2025, compared to 7.62% in Q2 2025 and 65.01% in Q1 2025.